Shiloh
Editor, Senior Moderator
Source: http://www.ctnow.com/health/sns-rt-us-sinovac-study-vaccinebre92d0hf-20130314,0,5810894.story
Sinovac vaccine meets study goal; shares jump 60 percent
Vrinda Manocha Reuters
11:05 a.m. EDT, March 14, 2013
(Reuters) - China-based Sinovac Biotech Ltd said a late-stage trial of its experimental vaccine for hand, foot and mouth disease (HFMD) met the main study goal of preventing the infection in infants between the ages of 6 months and 35 months.
The Sinovac stock jumped as much as 60 percent in early trading, making it the top percentage gainer on the Nasdaq. About 5 million shares changed hands by 1041 ET, nearly 85 times their 10-day average volumes.
The trial results showed an immune response to the infection in 95.4 percent of vaccinated subjects. The trial tested two doses of the vaccine in 10,000 healthy infants in China...
Sinovac vaccine meets study goal; shares jump 60 percent
Vrinda Manocha Reuters
11:05 a.m. EDT, March 14, 2013
(Reuters) - China-based Sinovac Biotech Ltd said a late-stage trial of its experimental vaccine for hand, foot and mouth disease (HFMD) met the main study goal of preventing the infection in infants between the ages of 6 months and 35 months.
The Sinovac stock jumped as much as 60 percent in early trading, making it the top percentage gainer on the Nasdaq. About 5 million shares changed hands by 1041 ET, nearly 85 times their 10-day average volumes.
The trial results showed an immune response to the infection in 95.4 percent of vaccinated subjects. The trial tested two doses of the vaccine in 10,000 healthy infants in China...